Riskpilot← Back to searchSign inGet full accessVenadoc AB
ABActiveOrg 5592202369Venavägen 20General medical practice activities · NACE 8621Est. 20191 employees
Revenue 2025
SEK 51K
+19% vs 2024
EBITDA margin
54.0%
-13% vs 2024
Equity ratio
81.5%
Financial strength
Net profit 2025
SEK 22K
-13% vs 2024
| Revenue | SEK 51K | +19% |
| EBITDA | SEK 27K | -13% |
| Net profit | SEK 22K | -13% |
| Total assets | SEK 89K | -2% |
| Equity | SEK 73K | -4% |
| Employees | 1 | — |
Legal name
Venadoc AB
Org number
5592202369
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
27 september 2019
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att, på konsultbasis, bedriva bemanningsuppdrag inom medicin och vård. Bolaget kommer även bedriva föreläsningar om livsstil, hälsa och ledarskap, uppdrag inom TV och media, friskvård, handel med friskvård- och sjukvårdsartiklar, förvaltning av lös och fast egendom, handel med värdepapper, och därmed förenlig verksamhet.
Address
Venavägen 20
Email
martin_tornqvist_1@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 55 | 59 | 47 | 43 | 51 |
| Staff expenses | — | −2 | −5 | −3 | −8 |
| EBITDA | 40 | 48 | 33 | 31 | 27 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 40 | 48 | 33 | 31 | 27 |
| Net financials | — | 0 | 0 | 0 | 0 |
| Profit before tax | 40 | 48 | 33 | 31 | 27 |
| Tax | −8 | −10 | −7 | −6 | −6 |
| Net profit | 32 | 38 | 26 | 25 | 22 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 100 | 105 | 93 | 91 | 89 |
| Equity | 82 | 89 | 77 | 76 | 73 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 18 | 17 | 16 | 15 | 16 |
| Total debt | 18 | 17 | 16 | 15 | 16 |
EBITDA margin
54.0%
This company
15.8%
Market median
+242% vs market
20212025
Equity ratio
81.5%
This company
38.2%
Market median
+113% vs market
20212025
Return on equity
29.9%
This company
18.4%
Market median
+63% vs market
20212025
Net profit margin
43.0%
This company
8.1%
Market median
+431% vs market
20212025
Asset turnover
0.57×
This company
1.12×
Market median
-49% vs market
20212025
Debt / equity
0.23×
This company
0.62×
Market median
+63% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Venadoc AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Martin Johan Törnqvist | Board of Directors | 0 companies |
| Linda Anna Nahlén | Deputy Board Member | 0 companies |